Ypsomed Holding AG (SWX:YPSN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 3.75B |
| Revenue (ttm) | 787.55M |
| Net Income (ttm) | 194.00M |
| Shares Out | 13.65M |
| EPS (ttm) | 14.21 |
| PE Ratio | 19.35 |
| Forward PE | 20.24 |
| Dividend | 2.20 (0.80%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 6,121 |
| Average Volume | 20,156 |
| Open | 274.00 |
| Previous Close | 275.00 |
| Day's Range | 269.00 - 275.00 |
| 52-Week Range | 260.50 - 441.50 |
| Beta | 0.94 |
| RSI | 30.61 |
| Earnings Date | Feb 11, 2026 |
About Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insu... [Read more]
Financial Performance
In fiscal year 2025, Ypsomed Holding AG's revenue was 748.87 million, an increase of 36.54% compared to the previous year's 548.46 million. Earnings were 87.50 million, an increase of 11.66%.
Financial StatementsNews
Ypsomed Holding AG (YPHDF) Q2 2026 Earnings Call Transcript
Ypsomed Holding AG (OTCPK:YPHDF) Q2 2026 Earnings Call November 12, 2025 4:00 AM EST Company Participants Sam Ghezelbash Simon Michel - CEO & Member of the Board Samuel Kunzli - Chief Financial Office...